APOE Genotyping
A one-time genetic test identifying which APOE variants you carry (E2, E3, E4). E4 is the strongest common genetic risk factor for late-onset Alzheimer's disease and also affects lipid handling.
Test once, ever. Knowing your genotype changes how aggressively you should manage cardiovascular and metabolic risk decades before symptoms — and E4 carriers may respond differently to saturated fat and alcohol.
Which APOE genotype did your report give?
What to do next. APOE is fixed, so the value is entirely in what you do with it. In every genotype the same levers dominate: ApoB, blood pressure, HbA1c, sleep quality, hearing, resistance training and social engagement. E4 carriers should treat those as more urgent rather than as a lost cause — and should know that genetic counselling exists for a reason, because this result lands harder than most.
What APOE Genotyping actually measures — the analyte, and the assay
The result is a pair of letters, and the letters come from two positions in one gene. APOE has three common alleles — epsilon 2, 3 and 4 — defined by the amino acids at residues 112 and 158 of the apolipoprotein E protein. Cysteine at both gives epsilon 2; cysteine then arginine gives epsilon 3; arginine at both gives epsilon 4. Everyone has two copies, so there are six possible genotypes.
The routine method genotypes those two sites rather than sequencing the gene. Real-time PCR with allele-specific probes, restriction fragment analysis, or a mass-spectrometry platform. Rare variants elsewhere in APOE — including ones with large effects on lipids — are invisible to it.
Some laboratories report the protein instead. Apolipoprotein E phenotyping by isoelectric focusing separates the isoforms by charge, and it can be misleading in people receiving blood products or with liver transplants, where the circulating protein no longer matches the person's own genotype.
There is nothing to measure over time and no units. Everything that follows on this page is about what the letters predict, which is the only question a genotype page can answer Rajicic Bumber 2025.
APOE Genotyping: what changes the blood, and what only changes the reading
What changes the genotype: nothing, ever. This is one of two pages in this cohort where the marker itself cannot move, and the practical consequence is that a repeat test has no purpose.
What the genotype changes in you:
- Lipid handling. ApoE is the ligand for hepatic remnant uptake. Epsilon 2 binds the receptor poorly, epsilon 4 avidly, and the consequence is a genotype-dependent LDL cholesterol: epsilon 4 carriers average higher and epsilon 2 carriers lower.
- Response to dietary fat. Genotype modifies how much serum cholesterol moves in response to dietary fat, cholesterol and cafestol — measured across controlled feeding studies Weggemans 2001.
- Response to a statin. APOE genotype and statin response were examined in the UK Biobank and the All of Us program, which is the scale at which a pharmacogenetic effect of this size can be seen Asiimwe 2025.
- Alzheimer disease risk, by a large margin. Epsilon 4 homozygosity has been characterized as representing a distinct genetic form of Alzheimer's disease rather than merely a risk factor, on the basis of near-complete biomarker penetrance and a predictable age of onset Fortea 2024, with the risk in homozygotes examined further in 2025 Reiman 2025.
- Type III hyperlipoproteinemia, which requires epsilon 2 homozygosity plus a second metabolic hit — most epsilon 2 homozygotes never develop it.
What changes only the report:
- Phenotyping instead of genotyping, in someone whose circulating apolipoprotein E does not come from their own liver.
- Allele dropout, the same technical failure that affects any targeted genotyping assay.
- Which risk figure the report quotes. Lifetime risk, risk by age 85, and odds ratios against an epsilon 3 homozygous reference are three different numbers describing the same genotype Reiman 2025.
- Whether the report separates heterozygotes from homozygotes. The risk difference between one epsilon 4 allele and two is large, and a report that says epsilon 4 positive has thrown that away Fortea 2024.
Reference interval or decision threshold — which kind of number APOE Genotyping is
Allele frequencies, not a reference interval. Epsilon 3 is the commonest allele worldwide; epsilon 4 is carried by roughly a quarter of people of European ancestry, with about 2–3% homozygous. A genotype this common cannot function as a diagnosis.
The risk estimates are probabilities in populations, and they differ by ancestry. The association between epsilon 4 and Alzheimer disease is weaker in some African-ancestry populations than in European ones, so a risk figure quoted without its source population is incomplete Rajicic Bumber 2025.
Homozygosity is the case where the framing genuinely changed. The 2024 analysis argued epsilon 4 homozygotes show such consistent biomarker changes and such a predictable onset distribution that the condition behaves like a genetic form of the disease rather than a risk state Fortea 2024; the 2025 discussion of risk in homozygotes engages directly with what that means for an individual Reiman 2025.
There is no threshold to act on and no treatment assigned by genotype. Nothing in current practice is started or withheld on the basis of an APOE result alone, with the partial exception of monitoring decisions around anti-amyloid therapies Rajicic Bumber 2025.
How you would know your APOE Genotyping was wrong — and when to redraw
Never, for the genotype. A second APOE test on the same person checks the laboratory, not the person — the only situation in which it is reasonable is a result that conflicts with a known family genotype.
What is worth retesting is everything downstream of it. Lipids respond to diet and drugs within weeks Weggemans 2001 Asiimwe 2025; blood pressure, glucose regulation and hearing are modifiable; and none of them is fixed by the genotype.
Conditions that must match for those: the same laboratory and the same fasting policy for the lipid work.
What would have to change for the genotype to mean something actionable:
- Carrying epsilon 4? The measurements that convert it into something you can act on are ApoB and Lp(a) — particle-based lipid risk with thresholds and treatments — not a repeat of the genotype Asiimwe 2025.
- Lipids raised on an epsilon 4 background? The response to dietary fat is genotype-modified, so a controlled dietary change followed by a repeat lipid panel at 6 to 8 weeks is an informative experiment Weggemans 2001.
- Carrying epsilon 2 with high triglycerides and a raised cholesterol? That combination raises type III hyperlipoproteinemia, and the lipid panel with ApoB is what characterizes it.
- Worried about cognition? Cognitive testing and the amyloid-related plasma markers — including p-tau217 — measure state; APOE measures predisposition, and the two answer different questions Fortea 2024.
What APOE Genotyping cannot tell you
It cannot diagnose Alzheimer disease and it cannot exclude it. Most people with the disease are not epsilon 4 homozygotes, and most epsilon 4 heterozygotes do not develop it Reiman 2025.
It cannot give a personal probability. Published risks are population averages stratified by age, sex and ancestry, and an individual's number is not in the data Rajicic Bumber 2025.
It cannot detect rare APOE variants, because the assay looks at two positions.
It cannot be undone. Unlike almost every other marker on this site, there is no intervention that changes the result — only interventions that change what happens around it.
The wrong inference readers actually draw is that the letters are a verdict. A genotype carried by a quarter of the population is a modifier of risk, the strongest effects are confined to homozygotes, and the actions available afterward — lipids, blood pressure, glucose, sleep, hearing, exercise — are the same actions that were available before the test Fortea 2024 Rajicic Bumber 2025 Hickey 2013.
Sources read for these sections
- Fortea J, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nature Medicine 2024 · PMID 38710950
- Reiman EM, et al. The Risk of Alzheimer Disease in APOE4 Homozygotes. JAMA Neurology 2025 · PMID 40227662
- Rajicic Bumber J, et al. Clinical Significance of APOE4 Genotyping: Potential for Personalized Therapy and Early Diagnosis of Alzheimer's Disease. Journal of Clinical Medicine 2025 · PMID 40943807
- Asiimwe IG, et al. APOE Genotype and Statin Response: Evidence From the UK Biobank and All of Us Program. Clinical and Translational Science 2025 · PMID 40763922
- Weggemans RM, et al. Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol. Atherosclerosis 2001 · PMID 11257255
- Hickey SE, et al. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genetics in Medicine 2013 · PMID 23288205
The plan of attack
In this order. Most people start at step four, which is why they change five things at once and learn nothing.
- Confirm the number is real
Nothing physiological affects this result. Your genotype is fixed. No fasting state, time of day, illness, supplement or medication changes it, and a repeat test returns the same answer. Worth stating plainly rather than leaving blank. Test once. Never repeat it. - Read it with its partner
Consider carefully before testing — this is information you can't un-know, and some people find it distressing. It can also affect certain insurance products. Genetic counseling is a reasonable step. Draw it alongside: ApoB (Apolipoprotein B), Lipoprotein(a) — Lp(a), hs-CRP (High-Sensitivity C-Reactive Protein). - Work out which direction is yours
If it's high — E4 carriers: increased Alzheimer's and cardiovascular risk. Important context: this is risk, not destiny — many E4 carriers never develop Alzheimer's, and lifestyle meaningfully modifies the trajectory.
If it's low — E2 is generally protective for Alzheimer's but associated with a specific dyslipidemia pattern. - Fix it in this order
Nutrition. E4 carriers appear more sensitive to saturated fat and alcohol; a Mediterranean-style pattern has the strongest supporting data. Tight glucose control matters more, not less.
Lifestyle. The modifiable levers are substantial: aerobic exercise, quality sleep (glymphatic clearance), blood pressure and glucose control, hearing protection, cognitive and social engagement, and avoiding head injury.
Supplements. Omega-3 (DHA) — evidence is stronger when started early rather than after cognitive decline. B vitamins if homocysteine is elevated.
Hormones. Manage ApoB aggressively — cardiovascular and cognitive risk overlap heavily. Discuss any hormone therapy decisions with a physician who knows your genotype.
Compounds. No peptide alters genotype. This is a risk-stratification and motivation tool.
Work down the list, not across it. Adding a compound on top of an unfixed diet is why generic protocols fail. - Retest
Never — it's fixed for life. Change one thing at a time, or the retest can't tell you which thing worked.
How to fix it
📚 Corder EH et al., Science 1993 — APOE4 and Alzheimer's risk. Lourida I et al., JAMA 2019 — lifestyle modifies genetic risk.
This page can tell you what could have made your APOE Genotyping wrong. It cannot tell you whether it did.
Everything above is free and stays free — the assay, what changes the reading rather than the blood, the retest window and the sources. What no page can do is look at your draw: which laboratory ran it, at what hour, what you were taking that week, and what else was flagged beside it. Every one of those changes the answer, and none of them is on any page. Bringing a real result to people who know that list is what the members' area is for.
Bring your result — $10/mo →🩸 Test your APOE Genotyping
Order directly through Marek Diagnostics — no doctor's visit needed, drawn at any Quest location in the US. Code CAMERON applies 10% off automatically.
Order this test — 10% off → Browse all 103 markers →What APOE Genotyping is usually tested alongside
One marker is a data point. These panels add the markers that make APOE Genotyping interpretable, name why each is on the list, and load the set into your cart at 10% off.
includes this + 4 more markers — You want the handful of genetic results that actually change what you do — tested once, never repeated.
includes this + 8 more markers — Family history of dementia, noticeable memory change, or you want the earliest possible read on brain health while there's still time to act.
What people use APOE Genotyping to decide
Nobody orders a test for its own sake. APOE Genotyping is on the test list for these pathways — each one links to what the pathway claims, and what its test list is read for before you spend anything on it.
BDNF isn't clinically measurable, but the things that suppress it are — inflammation, insulin resistance and poor sleep. ApoE status is a one-time test that changes how seriously you take this whole pathway.
ApoB counts atherogenic particles; LDL-C estimates the cholesterol inside them. When the two disagree — common in insulin resistance — ApoB is right and LDL-C is falsely reassuring.
Would you feel it? Symptoms APOE Genotyping helps explain
People search for how they feel, not for a marker. These are the complaints where this one is worth checking, and whether it is first-line or a follow-up.
Why your APOE Genotyping might be wrong
Most abnormal results are interference, not disease. Check these before you change anything. Each says whether the number is wrong (repeat it), badly timed (redraw it), or real with a cause.
Your genotype is fixed. No fasting state, time of day, illness, supplement or medication changes it, and a repeat test returns the same answer. Worth stating plainly rather than leaving blank.
Test once. Never repeat it.
APOE e4 raises lifetime Alzheimer's risk, substantially with two copies. But many e4 carriers never develop dementia, and most people with Alzheimer's are not e4 homozygotes. Population risk figures get repeated as personal probabilities, which they are not.
Interpret with a clinician. The modifiable risk factors matter more than the genotype does.
In some countries a genetic result can affect life, disability or long-term care insurance underwriting, and protections vary. It also carries information about blood relatives who did not consent to learn it.
Decide whether you want to know before the blood is drawn. This is the rare result that cannot be un-seen.
What APOE Genotyping means in combination
One marker tells you a little; combinations tell you the story. These are the named patterns this one takes part in.
Genuinely reassuring, and worth stating because the genotype alone frightens people. ε4 raises lifetime risk; a normal pTau-217 says the amyloid pathology those risk figures describe is not currently detectable. Many ε4 carriers never develop dementia.
Put the effort into the fourteen modifiable risk factors — hearing, blood pressure, glucose, exercise, sleep, alcohol, social connection. They account for far more than the genotype does, and unlike it they respond.
What to test next
These put APOE Genotyping in context — each with its own full breakdown.
Frequently asked questions
Genotype result: E2/E2, E2/E3, E2/E4, E3/E3 (most common), E3/E4, or E4/E4. Ranges vary by laboratory and assay — always compare to the range printed on your own report.
Informational, not optimizable. E3/E3 is the common baseline.
E4 carriers: increased Alzheimer's and cardiovascular risk. Important context: this is risk, not destiny — many E4 carriers never develop Alzheimer's, and lifestyle meaningfully modifies the trajectory.
E2 is generally protective for Alzheimer's but associated with a specific dyslipidemia pattern.
You can order APOE Genotyping directly through Marek Diagnostics without a doctor's visit — drawn at any Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically.
Where this goes next
This page is the free framework. The protocol itself — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.